拉米夫定和普通干扰素初始联合治愈HBeAg阳性CHB患者1例  

A case of CHB patients with HBeAg positive who was treated with initial combination of lamivudine and interferon

作　　者：郭鹏 刘园园 李小芳 詹一飞 郑秋莹 冯倩 石香玉 谭华炳 GUO Peng;LIU Yuan-yuan;LI Xiao-fang;ZHAN Yi-fei;ZHENG Qiu-ying;FENG Qian;SHI Xiang-yu;TAN Hua-bing(Department of Infectious Diseases, Institute of Liver Diseases, Renmin Hospital, HubeiUniversity of Medicine, Shiyan 442000, Hubei Province, China;Third Clinical College, Hubei University ofMedicine, Shiyan 442000, Hubei Province, China)

机构地区：[1]湖北医药学院附属人民医院肝病研究所感染性疾病科,湖北十堰442000 [2]湖北医药学院第三临床学院,湖北十堰442000

出　　处：《中国肝脏病杂志（电子版）》2018年第1期86-88,共3页Chinese Journal of Liver Diseases：Electronic Version

基　　金：2014年湖北医药学院附属人民医院创新团队项目(201404);湖北医药学院校级创新训练项目(2015XS06)

摘　　要：实现HBsAg转阴和转化是CHB治疗的理想终点。本文报告1例HBeAg阳性CHB患者初始联合拉米夫定和普通干扰素治疗,治疗48周后实现HBsAg转阴,在继续联合抗病毒治疗的基础上接种乙肝疫苗(0个月、1个月、6个月),64周时HBsAb达50mIU/ml,72周时达150mIU/ml,判定为临床治愈,停止抗病毒治疗。提示科学合理联合抗病毒治疗,必要时加用乙肝疫苗和免疫增强剂,可能使CHB患者达到临床治愈。Realization of HBsAg negative conversion and transformation is the ideal endpoint of CHBtherapy. We reported a case of CHB patients with HBeAg positive who was given combination treatment oflamivudine （LAM） and interferon （IFN） for 48 weeks, and HBsAg conversed to be negative. On the basis ofanti-viral treatment, the patients were inoculated with hepatitis B vaccine （0 month, 1 month and 6 month）.The level of HBsAb was 50 mIU/ml at 64 week and 150 mIU/ml at 72 week. The patients get clinical cureand discontinued antiretroviral treatment. Among the different possibilities contemplated, combined treatmentis effective in HBV infection. The effectiveness of combined treatment should be researched with hepatitis Bvaccine or mmunopotentiator, as occasion requires.

关 键 词：肝炎 乙型 慢性 乙型肝炎病毒E抗原 核苷(酸)类似物 干扰素 乙肝疫苗 联合治疗 

分 类 号：R512.62[医药卫生—内科学]